Literature DB >> 15557326

Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface.

Csilla Ozvegy-Laczka1, György Várady, Gabriella Köblös, Olga Ujhelly, Judit Cervenak, John D Schuetz, Brian P Sorrentino, Gerrit-Jan Koomen, András Váradi, Katalin Német, Balázs Sarkadi.   

Abstract

The human ABCG2 protein is an important primary active transporter for hydrophobic compounds in several cell types, and its overexpression causes multidrug resistance in tumors. A monoclonal antibody (5D3) recognizes this protein on the cell surface. In ABCG2-expressing cells 5D3 antibody showed a saturable labeling and inhibited ABCG2 transport and ATPase function. However, at low antibody concentrations 5D3 binding to intact cells depended on the actual conformation of the ABCG2 protein. ATP depletion or the addition of the ABCG2 inhibitor Ko143 significantly increased, whereas the vanadate-induced arrest of ABCG2 strongly decreased 5D3 binding. The binding of the 5D3 antibody to a non-functional ABCG2 catalytic center mutant (K86M) in intact cells was not affected by the addition of vanadate but still increased with the addition of Ko143. In isolated membrane fragments the ligand modulation of 5D3 binding to ABCG2 could be analyzed in detail. In this case 5D3 binding was maximum in the presence of ATP, ADP, or Ko143, whereas the non-hydrolysable ATP analog, adenosine 5'-(beta,gamma-imido)triphosphate (AMP-PNP), and nucleotide trapping by vanadate decreased antibody binding. In membranes expressing the ABCG2-K86M mutant, ATP, ADP, and AMP-PNP decreased, whereas Ko143 increased 5D3 binding. Based on these data we suggest that the 5D3 antibody can be used as a sensitive tool to reveal intramolecular changes, reflecting ATP binding, the formation of a catalytic intermediate, or substrate inhibition within the transport cycle of the ABCG2 protein.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557326     DOI: 10.1074/jbc.M411338200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

Authors:  Rupashree Sen; Karthika Natarajan; Jasjeet Bhullar; Suneet Shukla; Hong-Bin Fang; Ling Cai; Zhe-Sheng Chen; Suresh V Ambudkar; Maria R Baer
Journal:  Mol Cancer Ther       Date:  2012-07-09       Impact factor: 6.261

2.  Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists.

Authors:  Kenneth K W To; Brian Tomlinson
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

3.  The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding.

Authors:  Karin F K Ejendal; Ndeye Khady Diop; Linda C Schweiger; Christine A Hrycyna
Journal:  Protein Sci       Date:  2006-07       Impact factor: 6.725

4.  Cellular Stiffness as a Novel Stemness Marker in the Corneal Limbus.

Authors:  Tom Bongiorno; Jena L Chojnowski; James D Lauderdale; Todd Sulchek
Journal:  Biophys J       Date:  2016-10-18       Impact factor: 4.033

5.  Structure of the human multidrug transporter ABCG2.

Authors:  Nicholas M I Taylor; Ioannis Manolaridis; Scott M Jackson; Julia Kowal; Henning Stahlberg; Kaspar P Locher
Journal:  Nature       Date:  2017-05-29       Impact factor: 49.962

6.  Dynamic ABCG2 expression in human embryonic stem cells provides the basis for stress response.

Authors:  Zsuzsa Erdei; Balázs Sarkadi; Anna Brózik; Kornélia Szebényi; György Várady; Veronika Makó; Adrienn Péntek; Tamás I Orbán; Ágota Apáti
Journal:  Eur Biophys J       Date:  2012-08-01       Impact factor: 1.733

Review 7.  Structure and function of the human breast cancer resistance protein (BCRP/ABCG2).

Authors:  Zhanglin Ni; Zsolt Bikadi; Mark F Rosenberg; Qingcheng Mao
Journal:  Curr Drug Metab       Date:  2010-09       Impact factor: 3.731

8.  Dynamic vs static ABCG2 inhibitors to sensitize drug resistant cancer cells.

Authors:  Hui Peng; Jing Qi; Zizheng Dong; Jian-Ting Zhang
Journal:  PLoS One       Date:  2010-12-07       Impact factor: 3.240

9.  Arginine 383 is a crucial residue in ABCG2 biogenesis.

Authors:  Orsolya Polgar; Lilangi S Ediriwickrema; Robert W Robey; Ajay Sharma; Ramanujan S Hegde; Yongfu Li; Di Xia; Yvona Ward; Michael Dean; Csilla Ozvegy-Laczka; Balazs Sarkadi; Susan E Bates
Journal:  Biochim Biophys Acta       Date:  2009-05-03

10.  Characterization of conformation-sensitive antibodies to ADAMTS13, the von Willebrand cleavage protease.

Authors:  Zuben E Sauna; Chinyere Okunji; Ryan C Hunt; Tanvi Gupta; Courtni E Allen; Elizabeth Plum; Adam Blaisdell; Vahan Grigoryan; S Geetha; Robert Fathke; Kenji Soejima; Chava Kimchi-Sarfaty
Journal:  PLoS One       Date:  2009-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.